June 06, 2023
Another milestone achieved – Bentley sold its 300,000th BeGraft

After launching the first BeGraft in 2012, the product found its way quickly to the clinics used in the most advanced and challenging endovascular procedures. The BeGraft is available in over 80 countries and became the market leader in most of them. With this steep growth Bentley is experiencing, the company proudly announced the sale of its 300,000th BeGraft stent, which is a tremendous achievement.
Martijn Nugteren, Director Sales & Marketing at Bentley, is delighted with this six-figure number and mentioned in a statement “it is amazing what we have achieved with the BeGraft in such a short time, we were able to treat so many patients globally, giving them the best stent for the treatment of their vascular disease.” He also highlighted that “thanks to the acquisition of in mid-April, Bentley is ready for the future growth of the BeGraft covered stent portfolio, which is much needed with the expected new indication and state of the art pipeline that we have.”
The 300,000th BeGraft was sold to the company NovaHealth in Thailand, who is a proud partner of Bentley since 2015.
BePart of Bentley's exciting journey and upcoming milestones by following Bentley on . For product availability or further information, check or send an email to .